A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.
Authors: Jennifer Rachel Eads, Maria Pia Morelli, Daniel Olson, Jason Blair Litten, Stephanie H. Astrow, Meredith Pelster